The University of South Alabama (USA) has the only University hospital within a 150 mile radius of Mobile, Alabama on the Gulf Coast. It serves the urban population of a Gulf coast Port City and a surrounding rural deep south population of patients from Alabama, Southern Mississippi and the panhandle of Florida. It provides the only hospital service in the region which is willing and capable of providing oncologic care for patients regardless of payment capability. The hospital system has approximately 840 beds and 32 beds are in a designated adult oncology unit. Approximately 500 new cancer patients are seen yearly at this facility and subsequently followed in the Cancer Center following discharge. Approximately half of the population come from minority groups to include African Americans, native Americans and immigrants from Vietnam and Cambodia. The USA has been a designated MBCCOP since the inception of the program. The grant supports cancer treatment protocols programs, the administration and data management of cancer treatment protocols and cancer control programs at USA where the majority of cancer patients are female and one half are members of minority populations. Cancer treatment protocols are mostly associated with either the Southwest Oncology Group (SWOG) or the Pediatric Oncology Group (POG). However, treatment protocols of the National Surgical Adjuvant Breast and Bowel Program (NSABB) and the M.D. Anderson Program (MSKCC) are utilized whenever a SWOG protocol is unavailable for a patient. Currently over 400 living cancer patients are in active follow-up. USA keeps available about 150 active IRB approval cancer protocols for eligible patients at any given time. We do not engage in any studies sponsored by pharmaceutical firms. Affiliations were established with MSKCC and the University of Rochester in order to increase access to national cancer control programs. We have no difficulty in recruiting minority patients for cancer treatment protocols. However, recruitment of minority individuals to cancer control programs which involve either a procedure or a medication with potential side effects has been difficult. USA is a participant in both the Breast Cancer Prevention Trial (BCPT) and the Prostate Cancer Prevention Trial (PCPT). In these trials minority participation has been poor even though efforts for recruitment were aimed at the African American community via radio, newspaper, health fairs, churches and social organizations. Minority patients who were recruited were college education and relatively affluent. A population study of this observation suggested that """"""""fatalism"""""""" may play an important role in delayed diagnosis and failure to use cancer preventative means. Methods of interdiction are being initiated to ascertain whether they will motivate minority patients to seek medical attention at an early stage of disease and use methods of cancer prevention and early detection.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA052654-08
Application #
2712640
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J3))
Project Start
1990-09-14
Project End
2000-05-31
Budget Start
1998-06-26
Budget End
1999-05-31
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of South Alabama
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Mobile
State
AL
Country
United States
Zip Code
36688
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Malhotra, Binu; Moon, James; Kucuk, Omar et al. (2014) Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329. Head Neck 36:1712-7
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5

Showing the most recent 10 out of 97 publications